DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,728,680 Morozov Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,728,680 Morozov Et Al III USOO572868OA United States Patent (19) 11 Patent Number: 5,728,680 Morozov et al. 45 Date of Patent: *Mar. 17, 1998 54 METHODS FOR NORMALZNG NUMBERS 4,517,119 5/1985 Felix et al. OF LYMPHOCYTES 4,526,717 7/1985 Seipke et al., 4,571,336 2/1986 Houck et al. 4.579,840 4/1986 Hahn. (75) Inventors: Vyacheslav G. Morozov, Vladimir Kh. 4.599,231 7/1986 Milich et al.. Khavinson, both of St. Petersburg, 4,612,365 971986 Birr et al. Russian Federation 4,614,731 9/1986 Horecker . 4,621,135 11/1986 Trainin et al.. 73) Assignee: Cytoven J.V. Kirkland, Wash. 4,634,682 1/987 Erickson et al. 4,659,694 4/1987 Horecker. * Notice: The term of this patent shall not extend 4,696,915 9/1987 Horecker. beyond the expiration date of Pat. No. 4,699,898 10/1987 Gottlieb. 5.538,951. 4,711952 12/1987 Kasafirek et al. 4,722.999 2/1988 Handschumacher et al. 4,751.216 6/1988 Gottlieb. 21 Appl. No.: 452,411 4,752,602 6/1988 Lipsky et al. 22 Filed: May 26, 1995 4,814434 3/1989 Goldfarb . 4,826,680 5/1989 Jaeger. Related U.S. Application Data 4,904,643 2/1990 Brunetti et al. 4,910.296 3/1990 Birr et al., 63 Continuation-in-part of Ser. No. 337,341, Nov. 10, 1994, 4.946,945 8/1990 Wojdani. Pat. No. 5,538,951, and a continuation-in-part of Ser. No. 4,983,387 1/1991 Goldstein et al.. 278,463, Jul. 2, 1994, abandoned, which is a continuation 5,070,076 12/1991 Morozov et al. in-part of Ser. No. 257,495, Jun. 7, 1994, abandoned, which 5,538,951 7/1996 Morozov et al. ......................... 514/19 is a continuation of Ser. No. 783,518, Oct. 28, 1991, 5,569,585 10/1996 Goodwin et al. ........................... 435/6 abandoned, which is a continuation-in-part of Ser. No, 678,129, Apr. 1, 1991, abandoned, which is a continuation FOREIGN PATENT DOCUMENTS in-part of Ser. No. 415,283, filed as PCT/SU88.00255, Dec. 14, 1988, abandoned. WO 9006945 6/1990 WIPO . WO 92/17191 10/1992 WIPO 30 Foreign Application Priority Data WO 93,08815 5/1993 WIPO Dec. 30, 1987 SU U.S.S.R. ................................ 4352833 OTHER PUBLICATIONS 51 Int. Cla. A6K 38/OS Rodionov et al, Vestn, Dermoatol. Venerol, 1:42-43, 1990. 52) U.S. Cl. ................................... 514/19:514/9; 514/11 Stites & Terr, Basic & Clinical Immunology, Prentice Hall. 58) Field of Search ..................................... 514/9, 11, 19 Norwalk, 1991, pp. 272-281. Brostoss et al. Clinical Immunol, Gower Med. Pub. London. 56 References Cited 1991, p. 30.10. U.S. PATENT DOCUMENTS van der Zeijst et al., J. Exp. Med, 1978, 147:1253-1266. Anisimov et al. (1982) Mechanisms of Ageing and Devel 3,679,787 7/1972 Bergy et al., opment, 19:245-258. 4,002,602 /1977 Goldstein. Anisimov et al. (1989) Mechanisms of Ageing and Devel 4.00,148 3/1977 Goldstein. opment, 49.245-247. 4,077.949 3/1978 Goldstein. 4,079,127 3/1978 Goldstein et al.. Demidov et al. (1991) “Effects of Thymus Preparations and 4,116,951 9/1978 Wang. Antituberculous Drugs on Immunological Reactivity and the 4,120,951 10/1978 Goldstein. Course of Tuberculous Process in Experimental Animals". 4,133,804 1/1979 Bach et al. Probl. Tuberk... 12:52-54 (Chemical Abstracts 116 (17), 4,148,788 4/1979 Wang. Abstract No. 165824Y). 4,167,557 9/1979 Goldstein. Goldstein et al. (1972) Proc. Natl. Acad. Sci. USA. 4.261,886 4/1981 Goldstein et al.. 69:1800-1803. 4.264,571 4/1981 Goldstein et al. Grigoriants et al. (1991) "Immunocorrection in the Com 4.297.276 10/1981 Goldstein et al., 4,339.427 7/1982 Goldstein et al.. bined Treatment of Patients with Osteomyelities Developing 4,353,821 10/1982 Birr et al.. Following Combined Injuries to the Maxillofacial and Cran 4,374.828 2/1983 Folkers et al. iocerebral Areas". Stomatologia (Mosk), 5:53-54 (Medline 4,377,511 3/1983 Lopukhin et al.. Abstract No. 92188368). 4,388,234 6/1983 Horecker . 4.389.343 6/1983 Horecker. (List continued on next page.) 4,395,404 7/1983 Low et al. 4,396,605 8/1983 Birr. Primary Examiner-Lila Feisee 4,426,324 1/1984 Meienhofer. Assistant Examiner-Susan Ungar 4,427,783 1/1984 Newman et al. 57 ABSTRACT 4,428,938 1/1984 Kisfaludy et al.. 4,442,031 4/1984 Felix et al.. This invention provides methods for normalizing the num 4,466,918 8/1984 Birr et al.. bers of lymphocytes in animals by administering the dipep 4,470,926 9/1984 Birr et al., 4,500,450 2/1985 Seipke et al.. tide L-Glu-L-Trp. 4,504,415 3/1985 Felix et al., 4,505,853 3/1985 Goldstein et al.. 12 Claims, 8 Drawing Sheets 5,728,680 Page 2 OTHER PUBLICATIONS Belokrylov, G. et al., "Ability of some amino acids incor porated into protein to stimulate the thymus-dependent Iakovlev et al. (1991) "The Biochemical And Immunologi immune response” Eksp. Biol. Medit. 102:51-53 (1986). cal Indices in the Rehabilitation Period of the Victims of the Bespalov, V.G. et al., "Inhibiting effect of thymogen, a Accident on The Komsomolets Atomic Submarine", Woen, synthetic analog of thymalin, on the development of esopha Med. ZH, 9:28-33 (Medline Abstract No. 92101433). Khmelnitskii et al. (1991) "Morphofunctional Characteris gus and forestomach tumors induced by N-nitrososarcosine tics of the Immunocompetent System in Hypotrophy and Its ethyl ester in rats” Chem. Abstracts 111:23 Abstract No. Correction By Thymogen". Arkh. Patol. 53:24-27 (Medline 146389r (1989). Abstract No. 92171772). Gee, N.S. and Kenny, A.J., "Proteins of the kidney microvil Low et al. (1981) Proceedings of the National Academy of lar membranes' Biochem. J. 246:97-102 (1987). Science, 78:1162-1166. Jaroff, L. "Stop that Germ!" Time, pp.55-64 (May 23, Rodionov et al., (1991) “Natural Killer Activity in Patients 1988). with Chronic Dermatoses". Vestn. Dernatol. Venerol. 5:4-6, Pettit, G.R. in: Synthetic Peptides, vol. 3. Academic Press, (Biological Abstract vol. 92, Abstract No. 100385). NY. pp. 130, 134, 143, 424, 427, 429, and 434 (1975). Rodionov et al. (1990) "The Immunocorrective Therapy of Remington's Pharmaceutical Sciences. Mack Publishing Pyoderma Caused by Staphylococci Multiply Resistant to Co., Easton, PA. pp. 996-997, 1465-1469, 1553–1557 Antibiotics", Vestn. Dermatol. Wenerol. 1:42-45 (Medline (1980). Abstract No. 90224329). Sandström, E.G. and Kaplan, J.C.. "Antiviral therapy in Werner, G. H. et al. (1986) "Immunomodulating peptides." AIDS: Clinical pharmacological properties and therapeutic Experientia, 42:521-531. experience to date" Drugs 34:372-390 (1987). Aliev, M.G. et al., "Simulation of thymus dysfunction in Sievertsson, H. et al., "Synthesis of Di-and tripeptides and guinea pigs by using immunomodulators” Chem. Abstracts assay in Vivo for activity in the thyrotrol releasing hormone 116:664 Abstract No. 171986u (1992). and the luteinizing releasing hormone systems' J. Med. ASM News 56:368 (1990). Chem. 15(1):8-11 (1971). U.S. Patent Mar. 17, 1998 Sheet 1 of 8 5,728,680 L-Glu-L-Trp A/6 /4 - - 0 00 as 80 es a 60 40 & 20 O 0 0 20 30 40 50 60 0 80 TIME (HRS.) L-Glu-L-Trp + AMPICILLIN A/G As -- 0 -O-- 0 -O-- 00 -V- 000 O O 20 30 40 50 60 70 80 TIME (HRS.) U.S. Patent Mar. 17, 1998 Sheet 2 of 8 5,728,680 HRS. POST-CHALLENGE -- 0 A/6 WC -O-24 90 III, III 80 |A || || III 60 M II 50 |M|| || || || 40 MII-PH 30 A II AH-1H Us1H III e1 - O 00 l,000 DOSE (mcg/kg) L-Glu-L-Trp HRS. POST-CHALLENGE -- 0 -O- 24 -O- 48 - V - 72 p-Ho IIM III || || |A || || 1 |M|| ||U21|| AAI-21 U11 II || ||II /1 || || || A 1 ZY | | | | || A III O 00 1,000 DOSE (mcg/kg) L-Gly-L-Trp-AMPICILLIN U.S. Patent Mar. 17, 1998 Sheet 3 of 8 5,728,680 A/G 24 tl." s e s s t : A O IO 20 30 40 50 60 70 80 90 100 TIME (HRS) A/G 2A L-Glu-L-Trp--GENTAMYCIN 0 0 20 30 40 50 60 70 80 90 00 TIME (HRS.) U.S. Patent Mar. 17, 1998 Sheet 4 of 8 5,728,680 HRs POST-CHA.EGE -- 24 A/G 2C -O- 48 90 ---, 72 - 1||||IH || 1I - 50 1I-111T - II THIII ulti-HiIII III O 1II II 0. O 00 DOSE (mcg/kg) L-Glu-L-Trp HRS. POST - CHALLENGE - - 24 A/6 2 -O-96-O- 48 U-1 8 O III. 6 O 11|| 40 M1M || || 2O MM|| || || 0 MI, III100 1,000 DOSE (mcg/kg) L-Glu-L-Trp- GENTANYCIN U.S. Patent Mar. 17, 1998 Sheet 5 of 8 5,728,680 A/G 34 L-Glu--Tr"" -O--0. s 5CV s s 0 0 20 30 40 50 60 70 80 TIME (HRS) A/G 3A s 2 S s O IO 20 30 40 50 60 70 80 TIME (R.S.) U.S. Patent Mar. 17, 1998 Sheet 6 of 8 5,728,680 HRS. POST-CHALLENGE -- 24 A/G 3C -O- 48 -O-96 00 90 U-1H-1H 80 O - I 60 || | | | | || 50 III al-III 40 |A || ||U 30 A S1 20 LM-1 || Oc 4-1 I TTTI,O III100 I IIIl,000 DOSE (mcg/kg) L-Glu-L-Trp HRS.
Load more

Recommended publications
  • Trade-To-Generic Names
    LIST OF TRADE-TO-GENERIC NAMES Brand Name Generic Name Abraxane® Paclitaxel protein bound particles Adriamycin®, various Doxorubicin Adrucil® (various) Fluorouracil Alimta® Pemetrexed Alkeran® Melphalan Arimidex® Anastrozole Aromasin® Exemestane Arranon® Nelarabine Avastin® Bevacizumab Bexxar® Tositumomab BiCNU® Carmustine (BCNU) Blenoxane® Bleomycin Busulfex® Busulfan Injection Campath® Alemtuzumab Camptosar® Irinotecan (CPT-11) Casodex® Bicalutamide CeeNu® Lomustine (CCNU) Cerubidine® Daunorubicin Clolar® Clofarabine Cosmegen® Dactinomycin Cytadren® Aminoglutethimide Cytosar-U® Cytarabine (ara-C) Cytoxan®, various Cyclophosphamide Dacogen® Decitabine DaunoXome® Daunorubicin liposomal DepotCyt® Cytarabine Liposomal Doxil® Doxorubicin HCL (liposomal injection) DTIC-Dome® Dacarbazine (DTIC) Eldisine® Vindesine Eligard® Leuprolide acetate Ellence® Epirubicin Eloxatin® Oxaliplatin Elspar® Asparaginase EmCyt® Estramustine Erbitux® Cetuximab Etopofos® Etoposide Phosphate Eulexin® Flutamide Fareston® Toremifene Faslodex® Fluvestrant Femara® Letrozole Fludara® Fludarabine Gemzar® Gemcitabine Gleevec® Imatinib Gliadel® Carmustine Wafer Halotestin® Fluoxymesterone Last Updated on January 15, 2007 Brand Name Generic Name Herceptin® Trastuzumab Hexalen® Altretamine Hycamtin® Topotecan Hydrea® Hydroxyurea Idamycin® Idarubicin Ifex® Ifosfamide Intron A® Interferon alfa-2b Iressa® Gefitinib Leukeran® Chlorambucil Leukine® Sargramostim Leustatin® Cladribine Lupron depot® Leuprolide acetate depot Lupron® Leuprolide acetate Matulane® Procarbazine Megace®
    [Show full text]
  • Gy Total Body Irradiation Followed by Allogeneic Hematopoietic St
    Bone Marrow Transplantation (2009) 44, 785–792 & 2009 Macmillan Publishers Limited All rights reserved 0268-3369/09 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia F Zohren, A Czibere, I Bruns, R Fenk, T Schroeder, T Gra¨f, R Haas and G Kobbe Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine-University, Du¨sseldorf, Germany In this prospective study, we examined the toxicity and Introduction efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute The use of intensified conventional induction chemothera- lymphoblastic leukemia who undergo allogeneic hemato- pies in the treatment of newly diagnosed ALL in adult poietic stem cell transplantation. Fifteen patients received patients has led to initial CR rates of up to 90%. But, as fludarabine 30 mg/m2, cytarabine 2000 mg/m2, amsacrine some patients are even refractory to first-line therapy, the 100 mg/m2 on days -10, -9, -8 and -7, anti-thymocyte majority of the responding patients unfortunately suffer globulin (ATG-Fresenius) 20 mg/kg body weight on days from relapse. Therefore, the probability of long-term -6, -5 and -4 and fractionated total body irradiation disease-free survival is o30%.1–5 Risk stratification based 2 Â 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) on prognostic factors allows identification of high-risk before allogeneic hematopoietic stem cell transplantation. ALL patients with poor prognosis.6–12 Myeloablative At the time of hematopoietic stem cell transplantation, 10 conditioning therapy followed by allogeneic hematopoietic patients were in complete remission (8 CR1; 2 CR2), 3 stem cell transplantation (HSCT) is currently the treatment with primary refractory and 2 suffered from refractory of choice for these high-risk patients.13–15 A combination of relapse.
    [Show full text]
  • CCNU-Dependent Potentiation of TRAIL/Apo2l-Induced Apoptosis in Human Glioma Cells Is P53-Independent but May Involve Enhanced Cytochrome C Release
    Oncogene (2001) 20, 4128 ± 4137 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release Till A RoÈ hn1, Bettina Wagenknecht1, Wilfried Roth1, Ulrike Naumann1, Erich Gulbins2, Peter H Krammer3, Henning Walczak4 and Michael Weller*,1 1Laboratory of Molecular Neuro-Oncology, Department of Neurology, University of TuÈbingen, Medical School, TuÈbingen, Germany; 2Institute of Physiology, University of TuÈbingen, Medical School, TuÈbingen, Germany; 3Department of Immunogenetics, German Cancer Research Center, Heidelberg, Germany; 4Department of Apoptosis Regulation, German Cancer Research Center, Heidelberg, Germany Death ligands such as CD95 ligand (CD95L) or tumor apy may be an eective therapeutic strategy for these necrosis factor-related apoptosis-inducing ligand/Apo2 lethal neoplasms. Oncogene (2001) 20, 4128 ± 4137. ligand (TRAIL/Apo2L) induce apoptosis in radio- chemotherapy-resistant human malignant glioma cell Keywords: brain; apoptosis; neuroimmunology; cyto- lines. The death-signaling TRAIL receptors 2 kines; immunotherapy (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the non- death-inducing (decoy) receptors TRAIL-R3/DcR1 and Introduction TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the Death receptor targeting is an attractive approach of absence of a protein synthesis inhibitor, cycloheximide experimental treatment for solid tumors that are (CHX). Three of the 12 cell lines were still TRAIL/ resistant to radiotherapy and chemotherapy, including Apo2L-resistant in the presence of CHX.
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • CK0403, a 9‑Aminoacridine, Is a Potent Anti‑Cancer Agent in Human Breast Cancer Cells
    MOLECULAR MEDICINE REPORTS 13: 933-938, 2016 CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells YUAN-WAN SUN1, KUEN-YUAN CHEN2, CHUL-HOON KWON3 and KUN-MING CHEN1 1Department of Biochemistry and Molecular Biology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA; 2Department of Surgery, National Taiwan University Hospital, Taipei 8862, Taiwan, R.O.C.; 3Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, New York, NY 11439, USA Received November 11, 2014; Accepted October 22, 2015 DOI: 10.3892/mmr.2015.4604 Abstract. 3-({4-[4-(Acridin-9-ylamino)phenylthio]phenyl} reduced growth inhibitory activity under hypoxic conditions, (3-hydroxypropyl)amino)propan-1-ol (CK0403) is a which can induce autophagy. Collectively, the present results sulfur-containing 9-anilinoacridine analogue of amsacrine and supported that CK0403 is highly potent and more effective than was found to be more potent than its analogue 2-({4-[4-(acridin- CK0402 against estrogen receptor-negative and 9-ylamino)phenylthio]phenyl}(2-hydroxyethyl)amino) HER2-overexpressing breast cancer cell lines, suggesting its ethan-1-ol (CK0402) and amsacrine in the inhibition of the future application for chemotherapy in breast cancer. topoisomerase II-catalyzed decatenation reaction. A previous study by our group reported that CK0402 was effective against Introduction numerous breast cancer cell lines, and the combination of CK0402 with herceptin enhanced its activity in HER2(+) Breast cancer is the most common type of cancer diagnosed SKBR-3 cells. In order to identify novel chemotherapeutic agents in American women and is the second most common cause with enhanced potency, the present study explored the potential of cancer-associated mortality.
    [Show full text]
  • Phenotype Microarrays Panels PM-M1 to PM-M14
    Phenotype MicroArrays™ Panels PM-M1 to PM-M14 for Phenotypic Characterization of Mammalian Cells Assays: Energy Metabolism Pathways Ion and Hormone Effects on Cells Sensitivity to Anti-Cancer Agents and for Optimizing Culture Conditions for Mammalian Cells PRODUCT DESCRIPTIONS AND INSTRUCTIONS FOR USE PM-M1 Cat. #13101 PM-M2 Cat. #13102 PM-M3 Cat. #13103 PM-M4 Cat. #13104 PM-M5 Cat. #13105 PM-M6 Cat. #13106 PM-M7 Cat. #13107 PM-M8 Cat. #13108 PM-M11 Cat. #13111 PM-M12 Cat. #13112 PM-M13 Cat. #13113 PM-M14 Cat. #13114 © 2016 Biolog, Inc. All rights reserved Printed in the United States of America 00P 134 Rev F February 2020 - 1 - CONTENTS I. Introduction ...................................................................................................... 2 a. Overview ................................................................................................... 2 b. Background ............................................................................................... 2 c. Uses ........................................................................................................... 2 d. Advantages ................................................................................................ 3 II. Product Description, PM-M1 to M4 ................................................................ 3 III. Protocols, PM-M1 to M4 ................................................................................. 7 a. Materials Required .................................................................................... 7 b. Determination
    [Show full text]
  • ACNU-Based Chemotherapy for Recurrent Glioma in the Temozolomide Era
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2009 ACNU-based chemotherapy for recurrent glioma in the temozolomide era Happold, C Abstract: No standard of care for patients with recurrent glioblastoma has been defined since temo- zolomide has become the treatment of choice for patients with newly diagnosed glioblastoma. This has renewed interest in the use of nitrosourea-based regimens for patients with progressive or recurrent dis- ease. The most commonly used regimens are carmustine (BCNU) monotherapy or lomustine (CCNU) combined with procarbazine and vincristine (PCV). Here we report our institutional experience with nimustine (ACNU) alone (n = 14) or in combination with other agents (n = 18) in 32 patients with glioblastoma treated previously with temozolomide. There were no complete and two partial responses. The progression-free survival (PFS) rate at 6 months was 20% and the survival rate at 12 months 26%. Grade III or IV hematological toxicity was observed in 50% of all patients and led to interruption of treatment in 13% of patients. Non-hematological toxicity was moderate to severe and led to interruption of treatment in 9% of patients. Thus, in this cohort of patients pretreated with temozolomide, ACNU failed to induce a substantial stabilization of disease in recurrent glioblastoma, but caused a notable hematotoxicity. This study does not commend ACNU as a therapy of first choice for patients with recurrent glioblastomas pretreated with temozolomide. DOI: https://doi.org/10.1007/s11060-008-9728-9 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-10588 Journal Article Originally published at: Happold, C (2009).
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • The Emerging Role of Paclitaxel in Breast Cancer Therapy1
    Vol. 1, 247-256, March 1995 Clinical Cancer Research 247 Minireview The Emerging Role of Paclitaxel in Breast Cancer Therapy1 Andrew D. Seidman2 overexpressing subline of MCF-7 cells appears to result in the Breast and Gynecological Oncology Service, Memorial Sloan- development of 4.4-fold less resistance (6). Furthermore, in Kettering Cancer Center, New York, New York 10021 paclitaxel-resistant cells, the ratio of soluble to polymerized tubulin is greater than that observed in sensitive cells (7). Introduction Ongoing investigation should clarify the relationship between Multiple chemotherapeutic agents and regimens exist with tubulin alterations and resistance to taxanes. documented antitumor activity against breast cancer; however, In parallel with the development of clinical trials of paclitaxel- less than one in five patients with stage IV breast cancer are alive based combination regimens, in vivo and in vitro studies have 5 years from the first detection of distant metastases (1). Although examined combinations for cytotoxicity in several systems. In vitro improved response proportions have been observed, overall sur- studies in human MCF-7 breast carcinoma cells exposed to a LD vival for patients with metastatic breast cancer has not been sig- of paclitaxel for 24 h followed by a 1-h incubation with varying nificantly improved by the progress of the past three decades. Furthermore, despite the proven magnitude of benefit of adjuvant concentrations of doxorubicin showed less than additive cytotox- icity for the combination of paclitaxel and doxorubicin (8). On the systemic therapy in reducing the risk of recurrence (2), a significant fraction of patients with early stage breast cancer still will relapse other hand, when an AlT cell viability assay was used, others have and ultimately die of metastatic disease.
    [Show full text]
  • Relevance Network Between Chemosensitivity and Transcriptome in Human Hepatoma Cells1
    Vol. 2, 199–205, February 2003 Molecular Cancer Therapeutics 199 Relevance Network between Chemosensitivity and Transcriptome in Human Hepatoma Cells1 Masaru Moriyama,2 Yujin Hoshida, topoisomerase II ␤ expression, whereas it negatively Motoyuki Otsuka, ShinIchiro Nishimura, Naoya Kato, correlated with expression of carboxypeptidases A3 Tadashi Goto, Hiroyoshi Taniguchi, and Z. Response to nimustine was associated with Yasushi Shiratori, Naohiko Seki, and Masao Omata expression of superoxide dismutase 2. Department of Gastroenterology, Graduate School of Medicine, Relevance networks identified several negative University of Tokyo, Tokyo 113-8655 [M. M., Y. H., M. O., N. K., T. G., H. T., Y. S., M. O.]; Cellular Informatics Team, Computational Biology correlations between gene expression and resistance, Research Center, Tokyo 135-0064 [S. N.]; and Department of which were missed by hierarchical clustering. Our Functional Genomics, Graduate School of Medicine, Chiba University, results suggested the necessity of systematically Chiba 260-8670 [N. S.], Japan evaluating the transporting systems that may play a major role in resistance in hepatoma. This may provide Abstract useful information to modify anticancer drug action in Generally, hepatoma is not a chemosensitive tumor, hepatoma. and the mechanism of resistance to anticancer drugs is not fully elucidated. We aimed to comprehensively Introduction evaluate the relationship between chemosensitivity and Hepatoma is a major cause of death even in developed gene expression profile in human hepatoma cells, by countries, and its incidence is increasing (1). Despite the using microarray analysis, and analyze the data by progress of therapeutic technique (2), the efficacy of radical constructing relevance networks. therapy is hampered by frequent recurrence and advance of In eight hepatoma cell lines (HLE, HLF, Huh7, Hep3B, the tumor (3).
    [Show full text]
  • Title Second-Line Chemotherapy for Small-Cell Lung Cancer
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Second-line chemotherapy for small-Cell Lung Cancer Title (SCLC). Author(s) Kim, Young Hak; Mishima, Michiaki Citation Cancer treatment reviews (2011), 37(2): 143-150 Issue Date 2011-04 URL http://hdl.handle.net/2433/137220 Right © 2010 Elsevier Ltd Type Journal Article Textversion author Kyoto University Second-line Chemotherapy for Small-Cell Lung Cancer (SCLC) Young Hak Kim and Michiaki Mishima Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan For reprints and all correspondence: Young Hak Kim Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan Phone: +81-75-751-3830; Fax: +81-75-751-4643; E-mail: [email protected] Running title: Second-line Chemotherapy for SCLC Key words: small-cell lung cancer, relapsed, chemotherapy, second line, sensitive, refractory 1 Abstract Although small-cell lung cancer (SCLC) generally shows an excellent response to initial chemotherapy, most patients finally relapse and salvage chemotherapy is considered. Usually, the response to salvage chemotherapy significantly differs between sensitive and refractory relapse. Sensitive relapse is relatively chemosensitive and re-challenge with the same drugs as used in the initial chemotherapy has been used historically, while refractory relapse is extremely chemoresistant and its prognosis has been abysmal. To date, a number of clinical trials have been carried out for relapsed SCLC; however, the number of randomized trials is quite limited.
    [Show full text]
  • Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells
    International Journal of Bioscience, Biochemistry and Bioinformatics, Vol. 3, No. 3, May 2013 Nimustine Induces DNA Breaks and Crosslinks in NIH/3T3 Cells Lin-Na Zhao, Xue-Chai Chen, Yan-Yan Zhong, Qin-Xia Hou, and Ru-Gang Zhong study of drug-induced DNA cross-linking to reveal the Abstract—The relationship between carcinogenicity and difference between the nitrosourea anticancer mechanism DNA interstrand cross-links of nitrosoureas is poorly defined. and carcinogenic role. 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)- ACNU was discovered in 1974 as the first water-soluble 3- nitrosourea (ACNU, nimustine) is one of nitrosoureas used in nitrosourea compound [11], and mainly used in the clinic of the treatment of high-grade gliomas. It has the capability of causing DNA interstrand cross-links (ICLs) to kill cancer cells. glioblastoma patients before the introduction of But it can also cause the generation of secondary tumors with 8-carbamoyl-3-methylimidazo [5, 1-d]-1, 2, 3, carcinogenic side effects. In present study, we investigated DNA 5-tetrazin-4(3H) -one (temozolomide, TMZ) because of its interstrand cross-links, DNA double-strand breaks and cell high permeability across blood-brain barrier (BBB) and good cycle phase in NIH/3T3 cells from the primary mouse cytotoxic activity for gliomas [12]-[13]. BCNU always embryonic fibroblast cells induced by ACNU. This result induces two major types of genotoxic damage to the cell: indicated that the concentration of 60 and 75μg/ml of ACNU could be detected significantly ICLs, and the γ-H2AX has the DNA mono adducts and DNA interstrand cross-links.
    [Show full text]